SB-269970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies.

It is believed to act as a selective 5-HT7 receptor antagonist (EC50 = 1.25 nM) (or possibly inverse agonist).

A subsequent study in guinea pig at a concentration of 10 μM showed that it also blocks the α2-adrenergic receptor.

[1][2][3] The large difference in test concentrations however confirms the selectivity of SB-269970 for the 5-HT7 receptor.

[5] Possible therapeutic uses for SB-269970 and other 5-HT7 antagonists include the treatment of anxiety and depression,[6][7] and nootropic effects have also been noted in animal studies.